Immune responses against a new HIV-1 p24-gp41/pCAGGS-IL-12 DNA vaccine in Balb/c mice

Iranian Journal of Immunology

Volumn 9, Issue 2, 2012, Pages 86-97

  Roodbari, Fatemeh ^a,b   Sabahi, Farzaneh ^a   Sarbolouki, Mohamad Nabi ^c   Barkhordari, Farzaneh ^d   Adeli, Ahmad ^d   Jamedar, Amel ^a,e   Mahboudi, Fereidoun ^d  

^a TARBIAT MODARES UNIVERSITY   (Iran)

^b UNIVERSITY OF MAZANDARAN   (Iran)

^c UNIVERSITY OF TEHRAN   (Iran)

^d PASTEUR INSTITUTE OF IRAN   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Dendrosome; DNA vaccine; gp41; HIV 1; IL 12; p24

Indexed keywords

ADJUVANT; ANTIGEN P24; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HYBRID PROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; INTERLEUKIN 12; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDROSOME; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GP41 GENE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; P24 GENE; RECOMBINANT PLASMID; TH1 CELL; VIRUS GENE;

AIDS VACCINES; ANIMALS; CELLS, CULTURED; FEMALE; HIV CORE PROTEIN P24; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNIZATION; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-12; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

EID: 84871869881     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. UNAIDS 'World AIDS Day Report 2011', November 2011.
2. Sarrami-Forooshani R, Das SR, Sabahi F, Adeli A, Esmaeili R, Wahren B. Molecular analysis and phylogenetic characterization of HIV in Iran. J Med Virol. 2006; 78:853-63.
3. UNAIDS/WHO. Report on the global HIV/AIDS epidemic. December 2006. Islamic Republic of Iran.
4. Jamehdar SA, Sabahi F, Forouzaneh M, Haji-Abdolbaghi M, kazemnejad A, Edalt R. Application of SYBR-Green Real Time RT-PCR quantification of human immunodeficiency virus type-1 (HIV-1) and comparison with Cobas Amplicor Test. Modares Jouranl of Medical Sciences Summer. 2007; 10:43-50.
5. Jamehdar SA, Sabahi F, Forouzandeh M, Haji Abdolbaghi M, Kazemnejad A, Mahboudi F. Evaluation of a new, highly sensitive and specific primer set for reverse-transcriptase PCR detection of HIV-1 infected patients: Comparison with standard primers. J Biol Sci. 2007; 7:954-8.
6. UNAIDS/WHO. Report on the global HIV/AIDS epidemic. December 2009. UNAIDS/ WHO, Geneva, Switzerland.
7. Girard MP, Osmanov SK, Kieny MP. A review of vaccine research and development: The human immunodeficiency virus (HIV). Vaccine. 2006; 24:4062-81.
8. Giri M, Ugen KE, Weine DB. DNA Vaccines against Human Immunodeficiency Virus Type 1 in the Past Decade. Clin Microbiol Rev. 2004; 17:370-89.
9. Calarota SA, Weiner DB. Present status of human HIV vaccine development. AIDS. 2003; 17:573-84.
10. Estcourt MJ, McMichael AJ, Hanak T. DNA vaccines against Human Immunodeficiency virus type 1. Immunol Rev. 2004; 199: 144-55.
11. + T cell response to the HIV-env V3 loop epitope from multiple virus isolates by a DNA prime/vaccinia virus boost (rWR and MVA strains) immunization regime and enhancement by the cytokine IFN-γ. Virus Res. 2004; 105:11-22.
12. MacGregor RR, Boyer JD, Ugen KE, Tebas P, Higgins TJ, Baine Y. Plasmid vaccination of stable HIV-positive subjects on antiviral treatment results enhanced CD8 T-cell immunity and increased control of viral blips. Vaccine. 2005; 18; 23:2066-73.
13. Qiu JT, Song R, Dettenhofer M, Tian C, August T, Felber BK. Evaluation of Novel Human Immunodeficiency Virus Type 1 Gag DNA Vaccines for Protein Expression in Mammalian Cells and Induction of Immune Responses. J Virol. 1999; 73:9145-52.
14. Sarbolouki MN, Sadeghizadeh M. Dendrosomes: a novel family for transfection and therapy. J Chem Technol Biotechnol. 2000; 75:919-22.
15. Xiao Y, Lu Y, Chen YH. Epitope-Vaccine as a new strategy against HIV-1 mutation. Immunol lett. 2001; 77:3-6.
16. Bazhan SI, Belavin PA, Seregin SV, Danilyuk NK, Babkina IN, Karpenko LI. Designing and engineering of DNA-vaccine construction encoding multiple CTL-epitopes of major HIV-1 antigens. Vaccine. 2004; 22:1672-82.
17. Balenga NA, Zahedifard F, Weiss R, Sarbolouki MN, J Thalhamer, Rafati S. Protective efficiency of Dendrosomes as novel nano-sized adjuvants for DNA vaccination against birch pollen allergy. J Biotechnol. 2006; 124:602-14.
18. Dong XN, Xiao Y, Dierich MP, Chen YH. N-and C-domains of HIV1 gp41: mutation, structure and functions. Immunol Lett. 2001; 75:215-20.
19. Usam O, Xiao P, Ling H, Liu Y, Nakasone T, Hattori T. Properties of anti-gp41 core structure antibodies, which compete with sera of HIV-1-infected patients. Microbes Infect. 2005; 7:650-7.
20. Janvier B, Baillou A, Archinard P, Mounier M, Mandrand B, Goudeau A. Immune response to major epitope of p24 during infection with Human immunodeficiency virus type 1 and implication for diagnosis and prognosis. J Clin Microbiol. 1991; 29:488-92.
21. Li H, Liu ZQ, Ding J, Chen YH. Recombinant multiepitope vaccine induces predefined epitopes specific antibodies against HIV1. Immunol Lett. 2002; 84:153-7.
22. Zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB. Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines. J Virol. 2003; 77:6197-207.
23. Chattergoon MA, Saulino V, Shames JP, Stein J, Montaner LJ, Weiner DB. Co-immunization with plasmid IL-12 generatesa strong T-cell memory response in mice. Vaccine. 2004; 22:1744-50.
24. Gherardi MM, Ramirez JC, Rodríguez D, Rodríguez JR, Sano G, Zavala F. IL-12 delivery from Recombinant Vaccinia Virus Attenuates the Vector and Enhances the Cellular Immune Response Against HIV-1 Env in a Dose-Dependent Manner. J Immunol. 1999; 162:6724-33.
25. Heckman KL, Pease RL. Gene splicing and mutagenesis by PCR-driven Overlap extension. Nat Protoc. 2007; 2:924-32.
26. Horton RM. PCRmediated recombination and mutagenesis SOEing together tailor made genes. Mol Biotechnol. 1995; 3: 93-9.
27. Matsui M, Moriya O, Akatsuka T. Enhanced induction of hepatitis C virus-specific cytotoxic T lymphocytes and protective efficacy in mice by DNA vaccination followed by adenovirus boosting in combination with the interleukin-12 expression plasmid. Vaccine. 2003; 21:1629-39.
28. Karami A, Sarbolouki MN, Khatami F, Rastgoo N. CPG motif as an adjuvant in immunization of a recombinant plasmid encoding hepatitis C virus core protein. Iranian J Bitotechnol. 2005; 3:64-6.
29. Mahboudi F, Irina NA, Chevalier A, Ghadiri A, Adeli A, Amini-Bavil-Olyaee S. A serological screening assay of human immunodeficiency virus type 1 antibodies based on recombinant protein p24-gp41 as a fusion protein expressed in Escherichia coli. J Biotechnol. 2006; 125:295-303.
30. Kim JJ, Nottingham LK, Wilson DM, Bagarazzi ML, Tsai A, Morrison LD. Engineering DNA vaccine via co-delivery of costimulatory molecule genes. Vaccine. 1998; 16:1828-35
31. Plotkin. S.A, W.A. Ornestein. 2004. Vaccine IV, Saunders. 1219-58.
32. Agrawal L, Haq W, Hanson CV, Rao DN. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity. J Immune Based Ther Vaccines. 2003; 25; 1:5.
33. Muthumani K, Bagarazzi M, Conway D, Hwang DS, Manson K, Ciccarelli R. A Gag-Pol/Env-Rev SIV239 DNA vaccine improves CD4 counts, and reduce viral loads after pathogenic intrarectal SIV mac 251challenge in Rhesus Macaques. Vaccine. 2003; 21: 629-37.
34. Gheradi MM, Ramirez JC, Esteban M. Inteleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in an DNA prime-vaccinia virus boost vaccine regiment is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide. J Virol. 2000; 74: 6278-86.
35. Muthumani K, Kudchodkar S, Zhang D, Bagarazzi ML, Kim JJ, Boyer JD. Issues for improving multi plasmid DNA vaccines for HIV-1. Vaccine. 2002; 20:1999-2003.
36. Moore AC, Kong WP, Chakrabarti BK, Nabel GJ. Effects of Antigen and Genetic Adjuvants on Immune Responses to Human Immunodeficiency Virus DNA Vaccines in Mice. J Virol.2002; 76: 243-50.
37. Schadeck EB, Sidhu M, Egan MA, Chong SY, Piacente P, Masood A. A dose sparing effect by plasmid encoded IL-12 adjuvant on a SIVgag-plasmid DNA vaccine in rhesus macaques. Vaccine. 2006; 24:4677-87.
38. Stambas J, Brown SA, Gutierrez A, Sealy R, Yue W, Jones B. Long lived multi isotype anti-HIV antibody responses following a prime double boost immunization strategy. Vaccine. 2005; 23:2454-64.
39. Barouch DH, Letvin NL, Seder RA. The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses. Immunol Rev. 2004; 202:266-74.
40. Williman J, Lockhart E, Slobbe L, Buchan G, Baird M. The use of Th1 cytokines, IL-12 and IL-23, to modulate the immune response raised to a DNA vaccine delivered by gene gun. Vaccine. 2006; 24:4471-4.
41. Liljeqvist S, Ståhl S. Production of recombinant subunit vaccines: protein immunogens, live delivery systems and nucleic acid vaccines. J Biotechnol. 1999; 73:1-33.
42. Jin H, Li Y, Ma Z, Zhang F, Xie Q, Gu D. Effect of chemical adjuvants on vaccination. Vaccine. 2004; 22:2925-35.